secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001576885-23-000023
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q1 net loss $11.3M; cash $183.8M; Phase 1 ACU193 topline due Q3 2023
---------------------------------------------------------------------------

- Net loss of $11.3M for Q1 2023 vs $9.1M in Q1 2022; no revenue reported.
- Cash, equivalents and marketable securities $183.8M as of March 31, 2023, down from $193.4M at Dec 31, 2022.
- R&D expenses $8.7M (up from $6.0M) driven by ongoing Phase 1 INTERCEPT-AD trial of ACU193.
- Company expects to report topline Phase 1 data for ACU193 in early Alzheimer's in Q3 2023, with FDA interaction in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000023/0001576885-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000023/abos-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer